Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 12/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 10/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 8/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.69 |
| ▸ | CDK9 | P50750 | 6/20 | 0.69 |
| ▸ | FYN | P06241 | 3/20 | 0.60 |
| ▸ | PIM1 | P11309 | 5/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555692 | 1.00 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL30479652 | 0.87 | DYRK1A (0.77) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL102751 | 0.85 | DYRK1A (0.76) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL14653658 | 0.84 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL22421544 | 0.84 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL14765143 | 0.83 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL102417 | 0.82 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL19987076 | 0.82 | DYRK1A (0.71) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL102942 | 0.82 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL29436156 | 0.81 | DYRK1A (0.73) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4606433-A2 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Pharma America, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-3924351-B1 | CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF 2-((1R,4R)-4-((3-(3-(TRIFLUOROMETHYL)PHENYL) IMIDAZO[1,2-B]PYRIDAZIN-6-YL)AMINO)CYCLOHEXYL)PROPAN-2-OL | SUMITOMO PHARMA AMERICA INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289847-A1 | PIM KINASE INHIBITOR | Hangzhou Biosun Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 184/4885DYRK2 199/4885DYRK1B 185/4885 |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 184/4885DYRK2 199/4885DYRK1B 185/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | DYRK1A 500/4885DYRK2 403/4885DYRK1B 446/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, GK, PIM2 | DYRK1A 663/4885DYRK2 547/4885DYRK1B 693/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK1A 461/4885DYRK2 336/4885DYRK1B 451/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.